Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma Inc. (SILO) is a biopharmaceutical innovator developing novel therapies that combine traditional treatments with psychedelic research for conditions including PTSD and chronic pain. This dedicated news hub provides investors and researchers with essential updates on the company's clinical progress, strategic partnerships, and therapeutic advancements.
Access centralized, reliable information about Silo Pharma's pipeline developments, including its intranasal SPC-15 formulation for stress disorders and SP-26 implant technology for pain management. The page aggregates official press releases, research milestones, and financial disclosures while maintaining strict compliance with financial reporting standards.
Key updates cover clinical trial phases, intellectual property developments, university research collaborations, and regulatory filings. All content is verified through primary sources to ensure accuracy and timeliness for stakeholders tracking the company's progress in psychedelic-assisted therapeutics and advanced drug delivery systems.
Bookmark this page for streamlined access to Silo Pharma's latest announcements. For comprehensive tracking of the company's innovative approach to CNS disorder treatments, consider subscribing to Stock Titan's news alerts.
Silo Pharma (NASDAQ:SILO) has entered into a non-binding letter of intent with Hoth Therapeutics (NASDAQ:HOTH) to form a 50:50 joint venture targeting the $16 billion global obesity market. The collaboration focuses on developing a novel therapeutic platform based on glial cell line-derived neurotrophic factor (GDNF), exclusively licensed from the U.S. Department of Veterans Affairs and co-developed with Emory University.
The technology, protected under U.S. Patent No. 10,052,362, targets multiple conditions including obesity, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes. The partnership combines Hoth's regulatory expertise with Silo's translational capabilities to address a significant unmet need, as obesity affects over 40% of U.S. adults, with veterans being particularly impacted.
Hoth Therapeutics (NASDAQ: HOTH) and Silo Pharma (NASDAQ: SILO) have formed a 50/50 joint venture to develop and commercialize a novel obesity treatment licensed from the U.S. Department of Veterans Affairs. The therapy is based on Glial Cell Line-Derived Neurotrophic Factor (GDNF), targeting obesity and non-alcoholic fatty liver disease (NAFLD).
The technology, protected under U.S. Patent No. 10,052,362, aims to address a $100B+ market with potential applications for type 2 diabetes and central obesity. The partnership combines the VA's clinical infrastructure, Hoth's regulatory expertise, and Silo's translational capabilities to develop this first-in-class treatment targeting the neuroinflammatory root of obesity.
Silo Pharma (NASDAQ: SILO) has partnered with medical technology provider Resyca BV for a drug-device study of SPC-15, its lead asset for post-traumatic stress disorder (PTSD) treatment. The study will focus on the formulation-specific microchip-based nasal spray system used to deliver the drug.
The intranasal delivery system is designed to bypass the blood-brain barrier, potentially enabling faster therapeutic benefits with optimized safety. This study is expected to provide the final device data and documentation needed for the company's planned FDA IND submission in 2025.
Additionally, Silo is conducting two other SPC-15 studies: an IND-enabling GLP-compliant toxicology and toxicokinetics study, and an FDA-requested 7-day safety and toxicology large animal study.
Silo Pharma (NASDAQ: SILO) has successfully closed a $2 million public offering of 3,333,338 shares of common stock at $0.60 per share, along with Series A-1 and A-2 warrants. The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $0.60 per share. H.C. Wainwright & Co. served as the exclusive placement agent. The developmental stage biopharmaceutical company plans to use the net proceeds for general working capital purposes.
Silo Pharma (NASDAQ: SILO) has announced the pricing of a $2 million public offering consisting of 3,333,338 shares of common stock (or pre-funded warrants) along with Series A-1 and A-2 warrants. The offering is priced at $0.60 per share with associated warrants. Both Series A-1 and A-2 warrants have an exercise price of $0.60, with A-1 warrants expiring in 5 years and A-2 warrants in 18 months.
H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is expected to close around May 16, 2025. The company plans to use the net proceeds for general working capital purposes. The offering is made through an effective SEC registration statement on Form S-1.
Silo Pharma (NASDAQ: SILO) has selected Veloxity Labs to conduct bioanalytical work for its IND-enabling GLP toxicology and toxicokinetics study of SPC-15, the company's lead drug candidate. SPC-15 is being developed as an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).
The company plans to initiate the FDA IND process for SPC-15 in 2025, and upon approval, will advance to a Phase 1 clinical trial. CEO Eric Weisblum expressed confidence in Veloxity Labs' ability to deliver fast turnaround times and precise data needed for the IND submission.
Silo Pharma (NASDAQ: SILO) has initiated a crucial 7-day safety and toxicology study for its lead drug candidate SPC-15, an intranasal PTSD treatment, at Frontage Laboratories. The study aims to gather additional data for the company's upcoming FDA investigational new drug (IND) application. Silo is simultaneously conducting a separate IND-enabling GLP-compliant toxicology study.
The company plans to submit its IND application in 2025, and upon approval, will proceed with a first-in-human Phase 1 clinical trial. SPC-15's development is backed by an exclusive global license from Columbia University for worldwide development, manufacturing, and commercialization rights.
Silo Pharma announced positive results from its preclinical study of SP-26, a novel extended-release ketamine implant for fibromyalgia treatment. The study, conducted in minipigs, met all endpoints including safety, tolerability, and sustained drug release.
Key findings include:
- No adverse events reported, with animals maintaining healthy weight and normal behavior
- Sustained ketamine release for up to 22 days post-implantation
- Minimal tissue inflammation at implant sites
- Peak drug levels achieved within 1 hour
SP-26 aims to provide sustained, sub-psychedelic ketamine levels in an abuse-deterrent format, potentially becoming the first at-home injectable ketamine-based therapeutic. The successful preclinical results position Silo to advance toward clinical studies for chronic pain and mental health treatments.